Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects
Open Access
- 1 December 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 20 (6), 1502-1508
- https://doi.org/10.1002/hep.1840200620
Abstract
The effect on kidney function, vasoactive systems and ascites outcome of long-term treatment with propranolol plus isosorbide-5-mononitrate, a combined therapy proven more effective than propranolol alone in decreasing portal pressure in the cirrhotic patient, is unknown. Thirty cirrhotic patients who survived acute variceal bleeding and were treated with propranolol plus isosorbide-5-mononitrate were studied. Portal and systemic hemodynamics (n = 15), inulin clearance, free water clearance, plasma renin activity, aldosterone concentration and prostaglandin E2 excretion (n = 20) were measured before and after 3 mo of treatment. In addition, data on ascites outcome in the entire series after a mean follow-up of 9.6 mo were compared with those of 30 patients undergoing elective sclerotherapy and with those of 30 patients treated with propranolol alone matched for age, sex, presence of ascites, Child-Pugh class and mean follow-up length included in other randomized controlled trials. Combined therapy significantly decreased the hepatic venous pressure gradient and azygos blood flow. In addition, no changes in inulin clearance, free water clearance, plasma renin activity, aldosterone concentration and prostaglandin E2 excretion occurred, despite a mild decrease in mean arterial pressure. Moreover, no differences among the three groups of patients studied in ascites outcome were found. These results suggest that long-term treatment with propranolol plus isosorbide-5-mononitrate does not impair kidney function, vasoactive systems or ascites outcome in cirrhotic patients. (Hepatology 1994;20:1502-1508).Keywords
This publication has 30 references indexed in Scilit:
- Propranolol versus sclerotherapy in preventing variceal rebleeding: A randomized controlled trialGastroenterology, 1993
- Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertensionJournal of Hepatology, 1989
- Renal function and effective β-blockade in cirrhosis with ascitesJournal of Hepatology, 1989
- Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal VaricesNew England Journal of Medicine, 1987
- Sclerotherapy vs. Distal splenorenal shunt in the elective treatment of variceal hemorrhage: A randomized controlled trialHepatology, 1987
- Isosorbide 5-Mononitrate PharmacokineticsJMIR AI, 1987
- Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleedingJournal of Hepatology, 1986
- Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with CirrhosisNew England Journal of Medicine, 1981
- Prognostic value of spontaneous hyponatremia in cirrhosis with ascitesDigestive Diseases and Sciences, 1976
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973